Domenic A. Sica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Domenic A. Sica has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Rosemarie Mannino
The Department of Hematology/Oncology, Hunter Holmes McGuire VA Medical Center, Richmond, VA
1 shared publication
Latest Publications
- Open Access
- 5 September 2007
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 9 (9) , 723-727
Antihypertensive Medications and Anemia
Antihypertensive medication use can be associated with a reduction in hemoglobin concentration. The magnitude of such a change is generally small, but in certain instances it can be extreme enough to produce a clinically significant degree of anemia. The mechanistic basis for antihypertensive medication‐related changes in hemoglobin concentration include hemodilution, hemolytic anemia, and suppression of red blood cell production, as this occurs most commonly with angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers. A reduction in hemoglobin concentration in a patient who is receiving treatment for hypertension and does not have an obvious source of blood loss should account for potential antihypertensive therapy involvement.
- 5 September 2007
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 9 (9) , 723-727
Open AccessAntihypertensive Medications and Anemia
Antihypertensive medication use can be associated with a reduction in hemoglobin concentration. The magnitude of such a change is generally small, but in certain instances it can be extreme enough to produce a clinically significant degree of anemia. The mechanistic basis for antihypertensive medication‐related changes in hemoglobin concentration include hemodilution, hemolytic anemia, and suppression of red blood cell production, as this occurs most commonly with angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers. A reduction in hemoglobin concentration in a patient who is receiving treatment for hypertension and does not have an obvious source of blood loss should account for potential antihypertensive therapy involvement.